Abstract
Platelet-activating factor (PAF) is one of the most recently described potential mediators of acute or chronic renal disorders (for review Plante and Hebert 1988; Braquet et al. 1987). This finding may be of critical importance, not only for understanding new pathophysiologic pathways in the development of renal diseases, but also, and perhaps more importantly, for the eventual use of PAF antagonists in the prevention and treatment of such diseases (Braquet 1987).
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Benveniste J, Menson PM, Cochrane CG (1972) Leukocyte-dependent histamine release from rabbit platelets. The role of IgE, basophile and a platelet activating factor. J Exp Med 136:1356
Bessin P, Bonnet J, Apffel D, Soulard C, Desgroux L, Pelas I, Benveniste J (1983) Acute circulatory collapse caused by platelet-activating factor (PAF-Acether) in dogs. Eur J Pharmacol 68:403
Braquet P (1987) The Gingkolides: potent platelet-activating factor antagonists isolated from Gingko biloba L.: Chemistry, pharmacology and clinical applications. Drugs Future 12:643
Braquet P, Spinnewyn B, Braquet M, Bourgain RH, Taylor JE, Etienne A, Drieu K (1985) BN 52021 and related compounds: a new series of highly specific PAF-acether receptor antagonists isolated from Gingko biloba. Blood Vessels 16:559
Braquet P, Touqui L. Shen TY, Vargaftig BB (1987) Perspectives in platelet-activating factor research. Pharmacol Rev 39:97
Brezis M, Rosen S, Silva P, Epstein FH (1984) Renal ischemia: a new perspective. Kidney Int 26:375
Bricker NS, Fine LG, Kaplan M, Epstein M, Bourgoignie JJ, Light A (1978) “Magnification phenomenon” in chronic renal disease. N Engl J Med 299:1287
Camussi G, Tetta C, Derigitus C, Bussolino F, Segolomi G, Vercellone A (1982) Platelet-activating factor (PAF) in experimentally-induced rabbit acute serum sickness: role of basophilderived PAF in immune complex deposition. J Immunol 128:86
Camussi G, Tetta C, Coda R, Segoloni GP, Vercellone A (1984) Platelet-activating factorinduced loss of glomerular anionic charges. Kidney Int 25:73
DeWardener HE, Clarkson EM (1985) Concept of natriuretic hormone. Physiol Rev 65:658
Farquhar MG (1975) The primary glomerular filtration barrier: basement membrane or epithelial slits. Kidney Int 8:197
Foegh ML, Khirabadi BS, Rowles JR, Braquet P, Ramwell P (1986) Prolongation of cardiac allograft survival with BN 52021, a specific antagonist of platelet-activating factor. Transplantation 42:86
Harris RH, Gill JM (1981) Changes in glomerular filtration rate during complete ureteral obstruction in rats. Kidney Int 19:603
Hebert RL, Sirois P, Braquet P, Plante GE (1987) Hemodynamic effects of PAF-acether on the dog kidney. Prostaglandins Leukotrienes Med 26:189
Hebert RL, Sirois P. Plante GE (1988) Inhibition of PAF-induced renal hemodanymic and tubular dysfunctions with L 655240, a new thromboxane/prostaglandin endoperoxide antagonist. Prostaglandins, (in press)
Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM (1981) Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 241:F85
Hwang SB, Li CL, Lam MH, Shen TY (1985) Characterization of cutaneous vascular permeability induced by platelet-activating factor in guinea pigs and rats, and its inhibition by a platelet-activating factor receptor antagonist. Lab Invest 52:617
Ito S, Camussi G, Tetta C, Milgrom F, Andres G (1984) Hyperacute renal allograft rejection in the rabbit: the role of platelet-activating factor and of cationic proteins derived from polymorphonuclear leukocytes and from platelets. Lab Invest 51:148
Jobin J, Hemmings R, Plante GE (1978) Effect of renal vein pressure on urinary sodium and hydrogen excretion. Can J Physiol Pharmacol 56:30
Pirotzky E, Bidault J, Burtin C, Gubler MC, Benveniste J (1984a) Release of platelet-activating factor, slow reacting substance, and vasoactive species from isolated rat kidneys. Kidney Int 25:404
Pirotzky E, Ninio E, Bidault J, Pfister P, Benveniste J (1984b) Biosynthesis of platelet-activating factor. VI. Precursor of platelet-activating factor and acetyl transferase activity in isolated rat kidney cells. Lab Invest 51:567
Plante GE, Hebert RL (1988) Platelet-activating factor in renal physiology and pathophysiology. Interest of the Gingkolides. In: Biology and Clinical Perspectives Braquet P, Gingkolides (ed). Telesymposia Proceedings, (in press)
Plante GE, Hebert RL, Lamoureux C, Braquet P (1986) Hemodynamic effects of PAF-acether. Pharmacol Res Commun Suppl 18:173
Plante GE, Prevost C, Braquet P, Sirois P (1988a) Increased peritoneal permeability with PAF-acether. Proceedings of the 8th National Conference CAPD, (in press)
Plante GE, Lussier YA, Chainey A, Boisclair L, Sirois P, Braquet P (1988b) BN 52021 reduces the development of hypertension and prevents hypernatriuresis in “uremic rats” Prostaglandins Leukotrienes Med (in press)
Plante Ge, Sirois P, Braquet P (1988c) Platelet-activating factor antagonism with BN 52021 protects the kidney against acute ischemic injury. Prostaglandins leukotrienes Med (in press)
Scherf H, Nies AS, Schwertschlag U, Hughes M, Gerber JG (1986) Hemodynamic effects of platelet-activating factor on the dog kidney in vivo. Hypertension 9:82
Schlondorff D, Satriano JA, Hagege J, Perez J Baud L (1984) Effect of platelet-activating factor and serum treated zymosan on Prostaglandin E2 synthesis, arachidonic acid release and contraction of cultured rat mesangial cells. J Clin Invest 73:1227
Sirois P, Sirois M, Jancar S, Braquet P. PLante GE (1988) PAF increases vascular permeability in selected tissues: effect of BN 52021 and L-655240. In: There is a case for PAF-acether antagonists. Paris
Thomson C, Forbes CD, Prentice CRM, Kennedy AC (1974) Changes in blood coagulation and fibrinolysis in the nephrotic syndrome. Q J Med 43:399
Trew PA, Biava CG, Jacobs RP, Hopper J (1978) Renal vein thrombosis in membranous glomerulopathy. Incidence and association. Medicine (Baltimore) 57:69
Weisman SM, Felsen D, Vaughan ED (1985) Platelet-activating factor is a potent stimulus for renal Prostaglandin synthesis: possible significance in unilateral ureteral ligation. J Pharmacol Exp Ther 235:10
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Plante, G.E., Sirois, P. (1988). Platelet-Activating Factor in Renal Pathophysiology: The Effects of PAF Antagonists. In: Nigam, S.K., McBrien, D.C.H., Slater, T.F. (eds) Eicosanoids, Lipid Peroxidation and Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73424-3_7
Download citation
DOI: https://doi.org/10.1007/978-3-642-73424-3_7
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-18932-9
Online ISBN: 978-3-642-73424-3
eBook Packages: Springer Book Archive